 |
 |
|
|
|
 |
|
|
|
 |
 |
|
|
10/06/2005
|
|
BOSTON, October 6, 2005 - Seaflower Ventures, a venture capital group focused on early-stage life sciences investments, today announced that it has appointed Amin Ladak as a principal, further enhancing Seaflower's expertise in venture capital and start-up investing.
Prior to joining Seaflower Ventures, Amin was employed with FoldRx Pharmaceuticals, a venture-backed company in Cambridge, MA, where he was responsible for overall business management. Previously, he was Director of Venture Analysis at HealthCare Ventures, one of the world's largest healthcare venture capital firms. He also worked at Bayer Pharmaceuticals in the New Product/New Business Development Group. Amin holds a Master's degree in Management and Health from Yale University, an M.S. degree in Human Genetics and a B.S. degree in Microbiology & Immunology from McGill University.
"We are very pleased to announce Amin's appointment as a principal at Seaflower. His background and experience in investing and operating in early-stage biomedical companies further strengthens our investment team" said Jim Sherblom, Managing General Partner of Seaflower. "Amin's scientific training brings an expertise to Seaflower that we believe will be of great benefit in our evaluation of prospective investments."
About Seaflower Ventures
Seaflower Ventures is a venture capital firm based in a Waltham, Massachusetts that focuses on early-stage biomedical investing. Since inception in 1996, Seaflower has raised three funds. Recent news from Seaflower's portfolio includes the IPO of ViaCell (VIAC) in early 2005, the September 28th, 2005, announcement of a worldwide collaboration between RenaMed Biologics and Genzyme Corp. (GENZ) and the closing of Zelos Therapeutics' series B round in June of 2005. Please visit www.seaflower.com for more information.
|
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
